Could less radiation be better for anal cancer? new trial aims to find out

NCT ID NCT05902533

Ongoing Disease control Sponsor: University of Cincinnati Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests whether giving a lower dose of radiation to nearby lymph nodes can reduce side effects in people with anal cancer who are also receiving chemotherapy. The trial includes 33 adults with locally advanced anal cancer. The goal is to see if this approach lowers toxicity while still controlling the disease.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Radiation (reduced dose to lymph nodes) combined with chemotherapy drugs capecitabine and mitomycin C
What this could lead to: If successful, this could lead to a new standard of care that reduces painful side effects from radiation for anal cancer patients.
What could go wrong: This is a small, early-phase trial with only 33 participants, so results may not apply to everyone. Lowering radiation might also reduce its ability to control the cancer.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ANAL CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

anal carcinoma anus neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ANAL CANCER

Contacts and locations

Locations

Ohio State University Medical Center

Columbus, Ohio, 43210, United States
University of Cincinnati Medical Center

Cincinnati, Ohio, 45219, United States
University of Vermont

Burlington, Vermont, 05405, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.